We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

62 hedge funds and large institutions have $165M invested in Bolt Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

0.27% less ownership

Funds ownership: 4.77% → 4.51% (-0.27%)

13% less funds holding

Funds holding: 71 → 62 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

63% less capital invested

Capital invested by funds: $449M → $165M (-$284M)

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
62
Holders Change
-9
Holders Change %
-12.68%
% of All Funds
0.95%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
11
Increased
25
Reduced
12
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$8.69M
2
SCM
Suvretta Capital Management
New York
+$8.59M
3
Morgan Stanley
Morgan Stanley
New York
+$2.55M
4
BlackRock
BlackRock
New York
+$1.84M
5
Holocene Advisors
Holocene Advisors
New York
+$1M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$20.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.5M
3
SC
Samlyn Capital
New York
-$9.38M
4
ABG
Ally Bridge Group
New York
-$3.25M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$2.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$45K +$87.9K +463 +15,433%
Citigroup
52
Citigroup
New York
$35K +$41.8K +220 +155%
Legal & General Group
53
Legal & General Group
United Kingdom
$27K +$10.8K +57 +26%
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$22K +$20.3K +107 +88%
TRCT
55
Tower Research Capital (TRC)
New York
$21K +$34.4K +181 +532%
AIP
56
Ameritas Investment Partners
Nebraska
$9K – – –
Osaic Holdings
57
Osaic Holdings
Arizona
$9K +$13.5K +71 +222%
Northwestern Mutual Wealth Management
58
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
RSCM
59
Rock Springs Capital Management
Maryland
– -$20.9M -82,462 Closed
SC
60
Samlyn Capital
New York
– -$9.38M -37,082 Closed
ABG
61
Ally Bridge Group
New York
– -$3.25M -12,863 Closed
PAMS
62
Pictet Asset Management (Switzerland)
Switzerland
– -$2.35M -9,295 Closed
Millennium Management
63
Millennium Management
New York
– -$2.06M -8,157 Closed
SAM
64
Sectoral Asset Management
Quebec, Canada
– -$1.47M -5,796 Closed
Point72 Asset Management
65
Point72 Asset Management
Connecticut
– -$1.19M -4,698 Closed
ECM
66
Endurant Capital Management
California
– -$1.14M -4,502 Closed
TCM
67
Tekla Capital Management
Massachusetts
– -$823K -3,251 Closed
DCM
68
Dupont Capital Management
Delaware
– -$338K -1,337 Closed
State of Wisconsin Investment Board
69
State of Wisconsin Investment Board
Wisconsin
– -$190K -750 Closed
VF
70
Virtu Financial
New York
– -$184K -729 Closed
VEA
71
Virtus ETF Advisers
New York
– -$165K -651 Closed
Victory Capital Management
72
Victory Capital Management
Texas
– -$161K -638 Closed
Manulife (Manufacturers Life Insurance)
73
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$139K -551 Closed
MIM
74
MetLife Investment Management
New Jersey
– -$120K -476 Closed
MLICM
75
Metropolitan Life Insurance Company (MetLife)
New York
– -$91K -360 Closed
1 2
3
4

BOLT Hedge Fund Activity: Q4 2021 in Review

62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2021, worth a combined $165M — down 63% from $449M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BOLT and 11 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 25 added.

The largest buyer was Eventide Asset Management, adding an estimated $8.69M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $20.9M sold.

  • 62 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2021, down from 71 in Q3 2021.
  • Funds reported $165M of Bolt Biotherapeutics stock for Q4 2021, down 63% quarter-over-quarter.
  • 11 funds opened new Bolt Biotherapeutics positions in Q4 2021 and 20 closed out, a net change of -9 holders.
  • The largest Bolt Biotherapeutics buyer in Q4 2021 was Eventide Asset Management, an estimated $8.69M added.
  • The largest Bolt Biotherapeutics seller in Q4 2021 was Rock Springs Capital Management, an estimated $20.9M sold.

Based on aggregated 13F filings for Q4 2021.